A Homing Peptide That Finds and Targets Spinal Cord Injuries in Rats | Research

The takeaway

The peptide CAQK selectively homes to spinal cord injury sites in rats, accumulating at the damaged area within hours and offering a potential targeted drug delivery system for SCI.

1.0 mg/kg optimal dose
Medium dose showed best injury-site targeting among three doses tested

What the researchers found

CAQK selectively accumulated at the spinal cord injury site after intravenous injection, demonstrating dose-dependent targeting with the medium dose (1.0 mg/kg) showing optimal localization.

Why it matters

Spinal cord injuries are devastating and current treatments lack precision. A peptide that can specifically find and deliver drugs to the exact injury site could dramatically improve therapy while reducing side effects.

How the study worked

Preclinical animal study using 24 rats with C6 spinal cord hemicontusion injuries, testing fluorescently labeled CAQK at three doses via tail vein injection with tissue analysis.

What this study cannot tell us

Small animal model (rats) that may not translate directly to humans; only tested in acute injury settings; did not evaluate therapeutic cargo delivery or functional recovery outcomes.

How to read the evidence

Preclinical rat study with controlled injury model — provides proof of concept but requires validation in larger animals and humans.

When this study was published

Published in 2026, representing cutting-edge research in peptide-targeted SCI therapy.

The bigger picture

This work extends targeted peptide delivery from brain injuries to spinal cord injuries, potentially enabling a platform for precision nanomedicine in neurological trauma that could carry anti-inflammatory drugs, growth factors, or other therapeutics directly to where they are needed.

Questions still open

Does CAQK targeting work in chronic spinal cord injuries or only acute ones?
Can therapeutic drugs attached to CAQK actually improve functional recovery after spinal cord injury?

Common questions

What is CAQK and how does it work?

CAQK is a four-amino-acid peptide that naturally homes to injured tissue by binding to proteins exposed at damage sites. It acts like a GPS for injuries, carrying attached cargo directly to where healing is needed.

Could this peptide be used to treat spinal cord injuries in humans?

Not yet — this is early animal research. But if the targeting holds up in larger animals and humans, CAQK could carry anti-inflammatory drugs or growth factors directly to spinal cord injuries, potentially improving recovery.

Read the original research

Targeting peptide homes to spinal cord injury in a rat model.

The journal of trauma and acute care surgery, 100(2), 198-205

View on PubMed ↗Publisher’s paper ↗

Citation

Castillo, Jose A; Le, Michael Nhien; Huang, Kuan-Wei; Pivetti, Christopher; Vatoofy, Sina; Ratcliff, Amanda; Tran, Taylor; Bannerman, Solomon; Lee, Maya; Shahin, Mehrad; Loll, Emma; Clark, Kaitlin; Reynolds, Elizabeth; Dangan, Andrei M T; Uppuluri, Jay; Urreola, Gabriel; Wang, Aijun A; Russo, Rachel M. (2026). Targeting peptide homes to spinal cord injury in a rat model.. The journal of trauma and acute care surgery, 100(2), 198-205. https://doi.org/10.1097/TA.0000000000004819